Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs LY 3303560 (Primary) ; LY 3303560 (Primary) ; Florbetapir F 18; Flortaucipir-F-18
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Eli Lilly
- 31 Aug 2017 Planned End Date changed from 1 May 2020 to 1 Feb 2020.
- 31 Aug 2017 Planned primary completion date changed from 1 May 2020 to 1 Feb 2020.
- 03 May 2017 Planned End Date changed from 17 Apr 2020 to 1 May 2020.